3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzaldehyde | 856253-13-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzaldehyde
• 英文别名: 5-bromo-3-tert-butyl-2-hydroxy-6-methylbenzaldehyde
• CAS: 856253-13-9
• 化学式: C₁₂H₁₅BrO₂
• 分子量: 271.154
• InChiKey: BCWMDSSSVUIBPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzaldehyde 在 sodium tetrahydroborate 、 偶氮二甲酸二异丙酯 、 potassium tert-butylate 、 水 、 三苯基膦 、 copper dichloride 作用下， 以 四氢呋喃 、 乙醇 、 乙腈 为溶剂， 生成 ethyl (R)-2-(4-bromo-6-(tert-butyl)-2-(2-hydroxyethyl)-3-methylphenoxy)propanoate
  参考文献：
  名称：

  Asymmetric Induction via Short-Lived Chiral Enolates with a Chiral C–O Axis

  摘要：

  A novel method has been developed for the asymmetric cyclization of alkyl aryl ethers. The reactions were assumed to proceed via short-lived chiral enolate intermediates with a chiral C-O axis to give cyclic ethers with tetrasubstituted carbon in up to 99% ee. The half-life of racemization of the chiral enolate intermediate was roughly estimated to be similar to 1 s at -78 degrees C.

  DOI：

  10.1021/ja4018122
• 作为产物：
  描述：

  6-叔丁基间甲酚 在 N-溴代丁二酰亚胺(NBS) 、 三乙胺 、 magnesium chloride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzaldehyde
  参考文献：
  名称：

  Asymmetric Induction via Short-Lived Chiral Enolates with a Chiral C–O Axis

  摘要：

  A novel method has been developed for the asymmetric cyclization of alkyl aryl ethers. The reactions were assumed to proceed via short-lived chiral enolate intermediates with a chiral C-O axis to give cyclic ethers with tetrasubstituted carbon in up to 99% ee. The half-life of racemization of the chiral enolate intermediate was roughly estimated to be similar to 1 s at -78 degrees C.

  DOI：

  10.1021/ja4018122

文献信息

• [EN] METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B<br/>[FR] PROCEDES PERMETTANT DE TRAITER DES TROUBLES SENSIBLES AU RETINOIDE AU MOYEN D'INHIBITEURS SELECTIFS DE CYP26A ET DE CYP26B
  申请人：ALLERGAN INC

  公开号：WO2005058301A1

  公开（公告）日：2005-06-30

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了一种治疗患有视黄酸反应性障碍的个体的方法。在一个实施例中，一种方法包括向个体施用有效量的选择性CYP26B抑制剂，所述选择性CYP26B抑制剂相对于CYP26A至少具有10倍的选择性。在另一个实施例中，一种方法包括向个体施用有效量的选择性CYP26A抑制剂，所述选择性CYP26A抑制剂的化学公式如说明书所述。本发明还提供了用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂的筛选方法。
• Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
  申请人：Vasudevan Jayasree

  公开号：US20050176689A1

  公开（公告）日：2005-08-11

  Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

  本说明书提供的1至17式化合物可以特异性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。
• Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
  申请人：Vasudevan Jayasree

  公开号：US20050187298A1

  公开（公告）日：2005-08-25

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了治疗具有视黄醇响应性疾病的个体的方法。在一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26B抑制剂，该选择性CYP26B抑制剂相对于CYP26A具有至少10倍的选择性。在另一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26A抑制剂，该选择性CYP26A抑制剂具有在规范中列出的化学式。本发明还提供了筛选方法，用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂。
• [EN] Compounds having selective cyrochrome P450RA-1 or selective cytochrome P450RA-2 inhibitory activity and methods of obtaining the same
  申请人：ALLERGAN INC

  公开号：WO2005058798A3

  公开（公告）日：2006-02-16
• METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B
  申请人：ALLERGAN, INC.

  公开号：EP1696899A1

  公开（公告）日：2006-09-06